Jeff Yass’s Oasmia Pharmaceutical AB OASM Stock Holding History

Jeff Yass’s Portfolio OASM Stock Details OASM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-21,977	Closed	-$50K	–	11199
2019 Q1	$50K	Buy	+21,977	New	+$60.2K	﹤0.01%	8465
2018 Q3	–	Sell	-40,801	Closed	-$54K	–	10748
2018 Q2	$54K	Buy	40,801 +22,362	+121%	+$32.5K	﹤0.01%	9254
2018 Q1	$24K	Buy	+18,439	New	+$24.2K	﹤0.01%	9105

Other funds holding OASM

CLOS

Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.25B AUM 27.04% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Jeff Yass's OASM Position: Q2 2019 in Review

Jeff Yass sold out of Oasmia Pharmaceutical AB (OASM) in Q2 2019, closing a stake of 21,977 shares — an estimated $50K sold.

Jeff Yass first reported a position in OASM in Q1 2018 and held it in 3 quarters. The position peaked at $54K in Q2 2018. 4 funds tracked by Wall St. Rank hold OASM as of Q2 2019.

Jeff Yass reported no remaining Oasmia Pharmaceutical AB position as of Q2 2019 after selling out during the quarter.
Jeff Yass sold 21,977 Oasmia Pharmaceutical AB shares in Q2 2019, an estimated $50K.
Jeff Yass first reported a position in Oasmia Pharmaceutical AB in Q1 2018 and held it in 3 quarters.
Jeff Yass's Oasmia Pharmaceutical AB position peaked at $54K in Q2 2018.
4 funds tracked by Wall St. Rank held Oasmia Pharmaceutical AB as of Q2 2019.

Based on Susquehanna International Group's 13F filing for Q2 2019, filed 14 Aug 2019.